![Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial | Circulation Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial | Circulation](https://www.ahajournals.org/cms/asset/009d942c-8b1d-49f6-ab09-45a11064e4ed/circulationaha.121.056824.fig01.jpg)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial | Circulation
![European Society of Cardiology on Twitter: "#EMPEROR-Reduced trial: empagliflozin prevents both serious #heartfailure events and serious #kidneyfailure events in patients with #HFrEF https://t.co/uWuvzc6RuN #ESCCongress https://t.co/0OfrzxqP40" / Twitter European Society of Cardiology on Twitter: "#EMPEROR-Reduced trial: empagliflozin prevents both serious #heartfailure events and serious #kidneyfailure events in patients with #HFrEF https://t.co/uWuvzc6RuN #ESCCongress https://t.co/0OfrzxqP40" / Twitter](https://pbs.twimg.com/media/Eglv6_1XcAA1wNd.png)
European Society of Cardiology on Twitter: "#EMPEROR-Reduced trial: empagliflozin prevents both serious #heartfailure events and serious #kidneyfailure events in patients with #HFrEF https://t.co/uWuvzc6RuN #ESCCongress https://t.co/0OfrzxqP40" / Twitter
![European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter](https://pbs.twimg.com/media/E9z5zG2X0Ac_skY.png)
European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter
![Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the](https://onlinelibrary.wiley.com/cms/asset/67115d78-3543-482b-9f9d-ea437c46dab8/ejhf1596-fig-0001-m.jpg)
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the
![European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter](https://pbs.twimg.com/media/E9z52A8XEAYqfGr.png)
European Society of Cardiology on Twitter: "#EMPEROR-Pooled trial: pooled the results of the EMPEROR-Reduced and EMPEROR-Preserved trials on an individual patient level #ESCCongress https://t.co/U8zgLWqaqZ" / Twitter
![Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials | Circulation Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials | Circulation](https://www.ahajournals.org/cms/asset/57b67f19-9e46-4a6d-a472-412f97ba731d/circulationaha.121.056657.fig01.jpg)
Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials | Circulation
![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631642603427-LHGX5Z37VKPX9PGU0NLV/emperor-preserved+efficacy.png)
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631642606959-HU38G60JK7I3YZIF0JCM/emperor-preserved+safety.png)
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631638143617-8C6MG465PVBU2FQYEVXO/emperor-preserved+primary.png?format=1000w)
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
![Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial | Journal of the American College of Cardiology Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/7c4f8830-1e70-4a87-805a-08ce90915eb2/fx1.jpg)
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial | Journal of the American College of Cardiology
![A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction - American Journal of Cardiology A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction - American Journal of Cardiology](https://www.ajconline.org/cms/asset/17ad2b94-72a9-4c5e-99a0-dc6b641c4ea3/gr1.jpg)